CDK5 and prostate carcinoma: Indeed, combining CDK5 inhibitors with other agents, such as tilorone, presents a promising method to boost efficacy in prostate cancer.[38] Previous combination therapies targeting β‐catenin resulted in its degradation,[39] which was frequently associated with cytotoxicity, thus limiting their clinical applicability.